Titan Pharmaceuticals Corporate Bonds and Leverage Analysis

TTNP Stock  USD 3.63  0.01  0.27%   
Titan Pharmaceuticals holds a debt-to-equity ratio of 0.043. At this time, Titan Pharmaceuticals' Short Term Debt is relatively stable compared to the past year. As of 12/11/2024, Short and Long Term Debt is likely to grow to about 870.8 K, while Long Term Debt is likely to drop slightly above 283.9 K. . Titan Pharmaceuticals' financial risk is the risk to Titan Pharmaceuticals stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Titan Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Titan Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Titan Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Titan Pharmaceuticals' stakeholders.
For most companies, including Titan Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Titan Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Titan Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
0.8334
Book Value
4.368
Operating Margin
-2.4 K
Return On Assets
(1.73)
Return On Equity
(3.69)
As of 12/11/2024, Non Current Liabilities Other is likely to grow to about 1 M, while Total Current Liabilities is likely to drop slightly above 1.4 M.
  
Check out the analysis of Titan Pharmaceuticals Fundamentals Over Time.
To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.
View Bond Profile
Given the importance of Titan Pharmaceuticals' capital structure, the first step in the capital decision process is for the management of Titan Pharmaceuticals to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Titan Pharmaceuticals to issue bonds at a reasonable cost.

Titan Pharmaceuticals Debt to Cash Allocation

Titan Pharmaceuticals currently holds 565 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Titan Pharmaceuticals has a current ratio of 3.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Titan Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Titan Pharmaceuticals Total Assets Over Time

Titan Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Titan Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Titan Pharmaceuticals Debt Ratio

    
  5.87   
It seems most of the Titan Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Titan Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Titan Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Titan Pharmaceuticals Corporate Bonds Issued

Titan Short Long Term Debt Total

Short Long Term Debt Total

536,750

At this time, Titan Pharmaceuticals' Short and Long Term Debt Total is relatively stable compared to the past year.

Understaning Titan Pharmaceuticals Use of Financial Leverage

Titan Pharmaceuticals' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Titan Pharmaceuticals' current equity. If creditors own a majority of Titan Pharmaceuticals' assets, the company is considered highly leveraged. Understanding the composition and structure of Titan Pharmaceuticals' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last ReportedProjected for Next Year
Short and Long Term Debt Total565 K536.8 K
Net Debt-6.2 M-6.5 M
Short Term Debt565 K1.1 M
Long Term Debt298.8 K283.9 K
Long Term Debt Total4.6 M4.2 M
Short and Long Term Debt450 K870.8 K
Net Debt To EBITDA 0.86  1.31 
Debt To Equity 0.08  0.07 
Interest Debt Per Share 0.66  0.63 
Debt To Assets 0.06  0.06 
Long Term Debt To Capitalization 0.08  0.08 
Total Debt To Capitalization 0.07  0.07 
Debt Equity Ratio 0.08  0.07 
Debt Ratio 0.06  0.06 
Cash Flow To Debt Ratio(14.18)(14.89)
Please read more on our technical analysis page.

Pair Trading with Titan Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Titan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Titan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Titan Stock

  0.77JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.78LLY Eli LillyPairCorr

Moving against Titan Stock

  0.84BMY Bristol Myers SquibbPairCorr
  0.82GILD Gilead SciencesPairCorr
  0.71ESPR Esperion TherapeuticsPairCorr
  0.71XAIR Beyond AirPairCorr
  0.65CAH Cardinal HealthPairCorr
The ability to find closely correlated positions to Titan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Titan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Titan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Titan Pharmaceuticals to buy it.
The correlation of Titan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Titan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Titan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Titan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Titan Stock Analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.